Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Irinotecan, and Panitumumab in Advanced Biliary Tract Adenocarcinoma
NCT00948935Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2009
- Primary completion
- Sep 2014
- Modality
- Antibody Conjugates, Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, gemcitabine and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in biliary tract cancer (BTC) and cholangiocarcinoma (CCA), sponsored by Abramson Cancer Center. Primary endpoint: Progression-Free Survival Rate at 5 months. Started Apr 2009; status: completed.
02
Drugs
panitumumabgemcitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
biliary tract cancer (BTC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT00948935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948935.